Hedge funds, private equity firms, and venture capitalists have long relied on alternative data sources to gain an edge – satellite images to estimate foot traffic, credit card data to forecast earnings, even weather models to predict energy demand.
However, when it comes to analyzing data from healthcare and pharma, many investors hit a wall. Unlike other industries where data can be scraped and stitched together from open sources, healthcare demands a higher bar – both legally and ethically.
According to recent reporting from Reuters, many of the world’s most sophisticated hedge funds have sought to overcome this by actively hiring physicians and scientists to decode complex drug trials and spot market-moving insights before they hit the newswire.
Healthcare, after all, is one of the most opportunity-rich sectors in the market, but it’s also one of the most heavily regulated when it comes to data – and for good reason. Patient data are protected under the Federal government’s Health Insurance Portability and Accountability Act (HIPAA), which outlines strict standards for how patient information is stored, used, de-identified, and shared.
In practice, this means that even firms with in-house MDs or data scientists can’t simply buy data, run some numbers, and expect to derive informative results from their analyses. Every dataset must be carefully structured to protect individual privacy, and only qualified providers with deep expertise in healthcare compliance can offer access to legally usable, de-identified datasets. As well as ensuring full adherence to the law, compliance is critical for reputational risk management in an industry where one misstep can make headlines.
Still, for firms that get it right, the opportunity is massive.
Real-world healthcare data, such as medical claims, remittance records, and longitudinal treatment histories, can surface market trends long before they show up in earnings calls. Whether you’re analyzing the commercial performance of a new therapy or performing due diligence on a provider network, RWD gives investors a more complete, evidence-based picture — earlier in the research process than traditional sources alone can provide.
For private equity firms evaluating healthcare services companies – like surgical center chains or diagnostic labs – RWD reveals what’s truly going on operationally.
Instead of relying solely on top-line revenue projections, investors can evaluate:
RWD enables a deeper level of diligence: Are claims trending in the right direction? Are providers expanding into high-growth markets? Are there medical or pharmacy coding issues that could impact profit?
In an increasingly competitive market, this level of clarity is key to identifying upside – and spotting landmines early.
For VC firms investing in early-stage biotech or health tech startups, the challenge often lies in sizing opportunity and gauging real-world adoption.
While pitch decks presented to VCs might promise large addressable markets, RWD provides a reality check:
RWD helps VCs validate go-to-market strategies and forecast uptake based on real-world clinical behavior and trends. It’s especially valuable in identifying underserved geographies and patient segments whose needs may not be fully addressed by the current standard of care.
For lean VC teams, i.e., those without large data and analytics departments, access to well-structured healthcare data – without needing to build infrastructure for data storage and insights generation from scratch – can be a make-or-break factor.
At the same time, larger VC teams can leverage a direct and stable claims data feed to assess startups, develop market analysis and strategy, and optimize their portfolio companies strategies.
For hedge funds, RWD opens a powerful new window into healthcare performance and trends in the market.
Quantitative analysts use large historical claims feeds to build models and identify temporal and seasonal patterns. Fundamental analysts lean on RWD to monitor:
In a market where drug performance updates or utilization spikes can move stocks overnight, being able to benchmark claims volume and competitive share in near real time gives hedge funds a clear advantage.
Real-world data may be the key to unlocking healthcare insights – but not all data providers are equal. For investment teams, three things matter most:
Consistent data inputs equate with reliable insights. Long-term contracts and stable payer relationships ensure data quality over time – enabling refined trend analysis and accurate projections.
Sophisticated strategies require attention to detail. Fields like claim timestamps and pharmacy identifiers NPIs give analysts the visibility needed to differentiate signal from noise.
Not every fund wants raw feeds – and not every team can process them. Some want weekly medical and pharmacy data feeds dropped into a warehouse. Others require automated brand volume reports to conduct trend analysis. Flexibility in format and frequency is critical.
PurpleLab combines one of the largest and most diverse healthcare claims databases in the US – over 4 billion annual medical and pharmacy claims across 320 million annual patient lives – with intuitive tools that make analysis and insight generation straightforward, even for non-technical users.
Our platform is HIPAA-compliant by design, meaning you get instantly actionable real-world insights without compliance risk.
We offer:
As top firms snap up physicians and scientists to decode healthcare, the smart ones are also investing in the data infrastructure to power those insights. PurpleLab provides the trusted data foundation and tools you need to move faster, dig deeper, and invest smarter.